The human epidermal growth factor receptor 2 (HER2; encoded by ERBB2) is overexpressed in ~15–25% of human breast cancers and associates with a poor patient survival (Arteaga and Engelman, 2014; Haikala and Janne, 2021). This evidence concerns the gene ERBB2 and breast carcinoma.